Devil's Claw Benefits

Devil's claw — Harpagophytum procumbens DC., family Pedaliaceae — is a trailing perennial of the Kalahari sands of Namibia, Botswana and South Africa. The medicine is not the hooked fruit that gave the plant its name but the secondary storage roots: the fleshy tubers that hang off the main taproot like potatoes off a runner. Those are sliced and dried, and the bitter iridoid glycoside harpagoside is the marker compound used to measure how much drug is in the bottle.

Among herbs sold for joint and back pain, devil's claw sits unusually high on the evidence ladder. It has genuine randomised, double-blind, placebo-controlled trials — not one, several — and it has been put head to head against real pharmaceuticals: diacerein in osteoarthritis and rofecoxib (Vioxx) in low back pain. That is more than most botanicals can say.

It is also a herb where the honest summary contains two large caveats, and this hub exists to state them plainly rather than bury them. First, the European Medicines Agency has a monograph on devil's claw root and it is a traditional use monograph, not a well-established use one — the regulator looked at the same trials and concluded they were not sufficient to license the herb on efficacy grounds. Second, the dose that matters is milligrams of harpagoside, not milligrams of root, and commercial products vary by more than an order of magnitude on exactly that number. A great deal of disappointment with devil's claw is really disappointment with an under-dosed capsule.

Deep-Dive Articles
What the Drug Actually Is
The One Number That Matters
What the EMA Monograph Actually Authorises
Evidence Map — Where It Is Real, Where It Is Thin
Cautions in Brief
Key Research Papers
External Resources
Connections

Deep-Dive Articles

Four articles cover the ground in detail. If you are trying to decide whether to buy a bottle, read the dosing article first — it is the one that determines whether any of the rest applies to the product in your hand.

Osteoarthritis and Joint Pain

The four-month trial against diacerein, the Doloteffin surveillance studies, the 259-patient open study, and what the systematic reviews concluded — with every trial's size, extract, dose and duration stated.

Low Back Pain

The two WS 1531 placebo-controlled trials, the underpowered rofecoxib comparison, the Cochrane verdicts from 2006 to 2016, and the arithmetic of how many people you have to treat for one to become pain-free.

Harpagoside, Dosing and Extract Types

How to turn any label into milligrams of harpagoside per day, why an “X:1 ratio” is not a dose, what surveys found actually inside commercial products, and how the trial extracts differed from each other.

Safety, Interactions and Sustainability

Gastrointestinal upset, the peptic-ulcer and gallstone cautions, the animal cardiac data that underlies the arrhythmia warning, warfarin and P-glycoprotein, and the wild-harvest conservation problem in southern Africa.

What the Drug Actually Is

Three details about the raw material change how you read everything else.

It is the secondary tubers, not the taproot. The primary taproot is the plant's survival organ; the secondary tubers are the storage organs strung along lateral roots. Harvesters who take the secondary tubers and leave the taproot in the ground can return to the same plant in four to six years. Harvesters who dig out the whole plant kill it. That single technical distinction is the whole sustainability story, and it is covered in the safety and sustainability article.
Two species are traded under one name. Harpagophytum procumbens is the species named in the pharmacopoeias; H. zeyheri is a legitimate but chemically different relative that generally carries less harpagoside. European monographs accept both, and chemometric work has shown that commercial material is not always what the label says. Species substitution is one reason two bottles labelled the same way can behave differently.
The European Pharmacopoeia sets a floor, not a target. Dried devil's claw root must contain a minimum of 1.2 percent harpagoside to be sold as the pharmacopoeial drug. That is a quality floor for the raw herb. It is not the concentration used in the clinical trials, which used concentrated extracts running several times higher.

Chemically the root is a mixture. Harpagoside is the measured marker, accompanied by the related iridoids harpagide and procumbide, the phenylethanoid glycosides verbascoside (acteoside) and isoacteoside, plus flavonoids, phenolic acids and sugars. Laboratory work suggests the accompanying compounds contribute, which is why whole standardised extracts sometimes outperform pure harpagoside in cell assays — a point that recurs in the drug-interaction data, where commercial extracts inhibited a transporter that pure harpagoside barely touched.

The One Number That Matters

Every worthwhile devil's claw trial reported its dose in milligrams of harpagoside per day, and the successful ones cluster in a narrow band: roughly 50 to 60 mg of harpagoside daily, with one back-pain trial testing 100 mg and finding the higher dose gave the clearer signal. Here is what that meant in practice for the named preparations.

Trial preparation	Daily dose as sold	Harpagoside delivered	Implied strength
WS 1531 (dry extract)	600 mg extract	50 mg	about 8–9% harpagoside
WS 1531 (higher arm)	1,200 mg extract	100 mg	about 8–9% harpagoside
Doloteffin (aqueous extract)	2,400 mg extract	50–60 mg	about 2–2.5% harpagoside
Harpadol (cryoground root powder)	2,610 mg powder	not stated in the report	crude root, at least 1.2% by pharmacopoeia

Read the second and third rows together. Doloteffin needed four times as much extract as WS 1531 to deliver the same harpagoside. Both worked in trials; neither is “stronger” as a product. The milligrams on the front of the box told you nothing useful on their own. That is the trap.

The arithmetic you need is one line:

mg of extract per day × harpagoside percentage = mg of harpagoside per day.

A capsule of 400 mg extract standardised to 5 percent harpagoside delivers 20 mg per capsule, so three a day reaches 60 mg — squarely in the trial range. A capsule of 500 mg of plain root powder at the pharmacopoeial floor of 1.2 percent delivers 6 mg, so you would need eight or nine capsules a day to reach the same place. A bottle that says only “devil's claw extract 10:1” gives you no way to do the sum at all, and a ratio is not a dose. The full worked method, including how to compare cost per 50 mg of harpagoside across brands, is in the dosing article.

What the EMA Monograph Actually Authorises

Devil's claw is often described as “EMA approved,” and the phrasing does real work that the underlying document does not support. Here is the accurate version.

The European Medicines Agency's Committee on Herbal Medicinal Products (HMPC) maintains a European Union herbal monograph on Harpagophytum procumbens DC. and/or Harpagophytum zeyheri Decne., radix. The current version is Revision 1, adopted in 2016. European herbal monographs come in two flavours, and the difference is the whole point:

Well-established use — the herb has recognised efficacy backed by acceptable clinical evidence, under Article 10a of Directive 2001/83/EC. This is an efficacy judgement.
Traditional use — the preparation has been used safely for at least 30 years, of which 15 in the EU, and is plausible on the strength of long use. Registration under Articles 16a to 16i requires no demonstration of efficacy. The regulator is signing off on plausibility and safety, not on the herb working.

The devil's claw monograph is assessed under the traditional use articles. Its indications are worded as traditional herbal medicinal product claims: relief of minor joint pain, and relief of mild digestive disorders such as bloating and flatulence and temporary loss of appetite. The monograph restricts use to adults, and sets duration limits — consult a doctor if joint symptoms persist beyond about four weeks, or digestive symptoms beyond about two weeks.

The revision process makes the point sharper. During the 2016 consultation an industry association argued that the clinical data on certain defined devil's claw preparations were now good enough to move them into the well-established use category. The HMPC did not make that change. A regulator that had read every trial on the following pages looked at them and declined to license the herb on efficacy.

That is not a reason to dismiss devil's claw. It is a reason to hold two things at once: the trials are real and mostly favourable, and they were not judged strong enough to clear a pharmaceutical efficacy bar. Both statements are true, and any page that gives you only one of them is selling something.

Evidence Map — Where It Is Real, Where It Is Thin

Use	Best available evidence	Honest verdict
Osteoarthritis of knee and hip	A 122-patient four-month randomised double-blind trial against diacerein; a 250-patient and a 75-patient open surveillance study; a 259-patient open study; several systematic reviews	The best-supported use. But the only large, long, properly blinded trial was an active comparison with no placebo arm, so it shows non-inferiority to a modest drug rather than a proven effect size
Non-specific and chronic low back pain	Two placebo-controlled randomised trials of WS 1531 (118 and 197 patients, four weeks); an 88-patient pilot against rofecoxib; repeated Cochrane assessment	Real, replicated, short-term benefit at 50–100 mg harpagoside daily — but the absolute effect is small, the trials are four to six weeks, and Cochrane graded the certainty as moderate at best
Anti-inflammatory mechanism	Cell and animal work: suppression of TNF-α and COX-2 expression, inhibition of NF-κB and AP-1 signalling, free-radical scavenging	A coherent laboratory story. Whether the concentrations used in a dish are reached in an inflamed human joint after a capsule is not established
Digestive complaints and appetite	Traditional use; bitter-tonic pharmacology; one cell study on ghrelin receptor modulation	Traditional indication only. The EMA lists it; there are essentially no controlled human trials
Rheumatoid arthritis, gout, tendinopathy	Included as “general rheumatic disorders” in one open study; no dedicated randomised trials	Not established. Devil's claw has not been shown to modify autoimmune joint disease and is not a substitute for disease-modifying treatment
Cartilage repair or disease modification	None	No evidence at all. Devil's claw is a symptom treatment

Cautions in Brief

The full discussion, with the underlying studies, is in the safety article. The short version:

Gastrointestinal upset is the commonest adverse effect — diarrhoea, loose stools, nausea, fullness. In the trials it ran at roughly 8–10 percent, mild, and usually manageable by taking doses with food.
Peptic ulcer disease, gastritis and reflux: devil's claw is a bitter that stimulates gastric acid secretion. Avoid it if you have an active ulcer or erosive disease.
Gallstones and bile-duct disease: it also stimulates bile flow. Avoid, or use only with medical supervision.
Warfarin: a genuine, if thinly evidenced, concern. Case-level reports and pharmacological plausibility both point the same way. Do not combine without your prescriber's knowledge and INR monitoring.
Heart rhythm and conduction: animal studies found dose-dependent falls in blood pressure and heart rate, negative inotropy at higher doses, and clear effects on experimentally induced arrhythmias. This is animal data, but it is specific enough to warrant real caution in arrhythmia, conduction disease, and alongside antiarrhythmic drugs or digoxin.
P-glycoprotein and CYP substrates: commercial devil's claw preparations inhibited the ABCB1/P-glycoprotein transporter in cell culture and altered its expression on repeated exposure. Treat narrow-therapeutic-index drugs as a flag.
Pregnancy: avoid. Traditional use includes oxytocic reputation, safety data are absent, and the EMA monograph restricts use to adults with pregnancy and lactation not recommended.

Key Research Papers

Every PubMed identifier below was checked live against NCBI E-utilities before it was written — first author, title, journal and year all had to match. Where a source could not be confirmed that way, the entry carries a PubMed topic search instead of a number that might point at the wrong paper.

Randomised trials in osteoarthritis

Chantre P, Cappelaere A, Leblan D, Guedon D, Vandermander J, Fournie B. Efficacy and tolerance of Harpagophytum procumbens versus diacerhein in treatment of osteoarthritis. Phytomedicine. 2000;7(3):177–183. — 122 patients, four months, Harpadol six capsules daily versus diacerein 100 mg/day; no efficacy difference, less rescue medication and fewer adverse events on the herb.
Leblan D, Chantre P, Fournié B. Harpagophytum procumbens in the treatment of knee and hip osteoarthritis. Four-month results of a prospective, multicenter, double-blind trial versus diacerhein. Joint Bone Spine. 2000;67(5):462–467. — the same trial reported in a rheumatology journal, giving the dose as 2,610 mg/day.
Wegener T, Lüpke NP. Treatment of patients with arthrosis of hip or knee with an aqueous extract of devil's claw (Harpagophytum procumbens DC.). Phytotherapy Research. 2003;17(10):1165–1172. — 75 patients, 12 weeks, 2,400 mg aqueous extract (50 mg harpagoside); WOMAC total fell 22.9 percent. Uncontrolled.

Randomised trials in low back pain

Chrubasik S, Zimpfer C, Schütt U, Ziegler R. Effectiveness of Harpagophytum procumbens in treatment of acute low back pain. Phytomedicine. 1996;3(1):1–10. — 118 patients, four weeks, 50 mg harpagoside daily; 9 of 51 pain-free versus 1 of 54 on placebo, but the pre-specified rescue-medication endpoint was negative.
Chrubasik S, Junck H, Breitschwerdt H, Conradt C, Zappe H. Effectiveness of Harpagophytum extract WS 1531 in the treatment of exacerbation of low back pain. European Journal of Anaesthesiology. 1999;16(2):118–129. — 197 patients, four weeks, 50 versus 100 mg harpagoside versus placebo; pain-free counts 3, 6 and 10 respectively.
Chrubasik S, Model A, Black A, Pollak S. A randomized double-blind pilot study comparing Doloteffin and Vioxx in the treatment of low back pain. Rheumatology (Oxford). 2003;42(1):141–148. — 88 patients, six weeks, 60 mg harpagoside daily versus rofecoxib 12.5 mg/day; no significant difference, and the authors concluded far larger numbers would be needed to show equivalence.

Systematic reviews and regulatory-grade assessments

Gagnier JJ, Chrubasik S, Manheimer E. Harpagophytum procumbens for osteoarthritis and low back pain: a systematic review. BMC Complementary and Alternative Medicine. 2004;4:13.
Oltean H, Robbins C, van Tulder MW, Berman BM, Bombardier C, Gagnier JJ. Herbal medicine for low-back pain. Cochrane Database of Systematic Reviews. 2014;(12):CD004504.
Gagnier JJ, Oltean H, van Tulder MW, Berman BM, Bombardier C, Robbins CB. Herbal medicine for low back pain: a Cochrane review. Spine. 2016;41(2):116–133.
Brien S, Lewith GT, McGregor G. Devil's claw (Harpagophytum procumbens) as a treatment for osteoarthritis: a review of efficacy and safety. Journal of Alternative and Complementary Medicine. 2006;12(10):981–993.
Chrubasik S, Conradt C, Black A. The quality of clinical trials with Harpagophytum procumbens. Phytomedicine. 2003;10(6–7):613–623. — a critique of the trial literature written by its most prolific investigator.

Chemistry, mechanism and product quality

Mncwangi N, Chen W, Vermaak I, Viljoen AM, Gericke N. Devil's claw — a review of the ethnobotany, phytochemistry and biological activity of Harpagophytum procumbens. Journal of Ethnopharmacology. 2012;143(3):755–771.
Fiebich BL, Muñoz E, Rose T, Weiss G, McGregor GP. Molecular targets of the antiinflammatory Harpagophytum procumbens (devil's claw): inhibition of TNFα and COX-2 gene expression by preventing activation of AP-1. Phytotherapy Research. 2012;26(6):806–811.
Mncwangi NP, Viljoen AM, Zhao J, Vermaak I, Chen W, Khan I. What the devil is in your phytomedicine? Exploring species substitution in Harpagophytum through chemometric modeling. Phytochemistry. 2014;106:104–115.
Menghini L, Recinella L, Leone S, et al. Devil's claw (Harpagophytum procumbens) and chronic inflammatory diseases: a concise overview on preclinical and clinical data. Phytotherapy Research. 2019;33(9):2152–2162.

Safety, interactions and sustainability

Vlachojannis J, Roufogalis BD, Chrubasik S. Systematic review on the safety of Harpagophytum preparations for osteoarthritic and low back pain. Phytotherapy Research. 2008;22(2):149–152.
Circosta C, Occhiuto F, Ragusa S, et al. A drug used in traditional medicine: Harpagophytum procumbens DC. II. Cardiovascular activity. Journal of Ethnopharmacology. 1984;11(3):259–274. — the rat and rabbit-heart study behind the cardiac caution.
Romiti N, Tramonti G, Corti A, Chieli E. Effects of devil's claw (Harpagophytum procumbens) on the multidrug transporter ABCB1/P-glycoprotein. Phytomedicine. 2009;16(12):1095–1100.
Stewart KM, Cole D. The commercial harvest of devil's claw (Harpagophytum spp.) in southern Africa: the devil's in the details. Journal of Ethnopharmacology. 2005;100(3):225–236.

Live PubMed Searches

External Resources

Connections

All Herbs
Devil's Claw — the main topic page
Boswellia — the other well-trialled anti-inflammatory resin
Turmeric — the most-studied botanical for joint pain
Willow Bark — the salicylate route to the same problem
Ginger — a milder anti-inflammatory with knee-OA data
Cat's Claw — a different “claw,” a different plant entirely
Orthopedics — musculoskeletal conditions
Osteoarthritis
Low-Back Pain
Rheumatology

Back to Table of Contents